Earning Preview: BillionToOne, Inc. this quarter’s revenue is expected to increase by 0.90%, and institutional views are bullish

Wells Fargo Reaffirms Their Hold Rating on BillionToOne, Inc. Class A (BLLN)

J.P. Morgan Sticks to Their Buy Rating for BillionToOne, Inc. Class A (BLLN)

Billiontoone SVP Sales Nancy Joann Johnson Disposes of 14,199 Common Shares Worth $1.82 Million

Billiontoone Appoints Ethan Dmitrovsky, Md, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar

Press Release: Billiontoone Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar

Billiontoone CTO David Tsao Reports Disposal of 22,000 Common Shares Worth $2.75 Million

Billiontoone to Report Q2 2026 Results, Host Conference Call

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026

Billiontoone Chief Product Officer Sakakibara Shan Riku Disposes of 8,000 Common Shares for $1 Million

U.S. Research Roundup-applied Materials, CME Group, NASDAQ

Billiontoone Chairman and CEO Oguzhan Atay Disposes of 25,000 Common Shares Worth $3.05 Million

Billiontoone SVP Sales and Commercial Operations Nancy Joann Johnson Sells 801 Shares for $100,036.87

Billiontoone SVP of Laboratory Operations John Roderick Ten Bosch Disposes of 1,416 Common Shares for $169,920

Billiontoone Study Finds Northstar Response Ctdna Test Outperforms Imaging in Predicting Immunotherapy Outcomes

Billiontoone Initiated at Buy by Guggenheim

BillionToOne price target raised to $125 from $120 at Guggenheim

Billiontoone Chief Product Officer Sakakibara Shan Riku Disposes of 8,000 Common Shares Worth $880,000